Tirzepatide Is not indicated for use in patients with type 1 diabetes mellitus.
- TRADE NAME: Mounjaro (Eli Lilly and Co)
- INDICATIONS:
Glycemic control in adults with type 2 diabetes mellitus.
Adjunct for the treatment of obesity and for weight loss management in defined populations and health conditions.
- CLASS: Anti-obesity / weight loss pharmacotherapy, Antidiabetic, Glucagon-like peptide-1 (GLP-1) receptor agonist
- HALF-LIFE: ~ 5 days
- FDA APPROVAL DATE: 05/13/2022
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Tirzepatide delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. - PREGNANCY: Available data with tirzepatide use in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.
- See adverse reactions attributed to class:
WARNING: RISK OF THYROID C-CELL TUMORS
TIRZEPATIDE CAUSES THYROID C-CELL TUMORS IN RATS. IT IS UNKNOWN WHETHER TIRZEPATIDE CAUSES THYROID C-CELL TUMORS, INCLUDING MEDULLARY THYROID CARCINOMA, IN HUMANS AS THE HUMAN RELEVANCE OF TIRZEPATIDE-INDUCED RODENT THYROID C-CELL TUMORS HAS NOT BEEN DETERMINED.
TIRZEPATIDE IS CONTRAINDICATED IN PATIENTS WITH A PERSONAL OR FAMILY HISTORY OF MEDULLARY THYROID CARCINOMA IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA SYNDROME TYPE 2. COUNSEL PATIENTS REGARDING THE POTENTIAL RISK OF MEDULLARY THYROID CARCINOMA AND SYMPTOMS OF THYROID TUMORS.
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of tirzepatide in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/22/2025
